Inhibition of c-met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma

Current Cancer Drug Targets

Volumn 10, Issue 3, 2010, Pages 332-342

  Kenessey, I ^a,b   Keszthelyi, M ^c   Kramer Z ^a,b   Berta, J ^c,g   Adam A ^a   Dobos, J ^b   Mildner, M ^d   Flachner, B ^e   Cseh, S ^e   Barna, G ^a   Szokol, B ^f   Orfi, L ^f   Keri G ^f   Dome B ^c,g   Klepetko, W ^g   Timar J ^a,b   Tovari J ^b,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^d Universitatsklinik fur Dermatologie   (Austria)

^e TargetEx Ltd   (Hungary)

^f Vichem Chemie Ltd   (Hungary)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C met; Human malignant melanoma; Metastasis; SU11274; Tyrosine kinase inhibitor

Indexed keywords

N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; LIVER METASTASIS; MELANOMA; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN TARGETING; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FOCAL ADHESIONS; HUMANS; INDOLES; LIVER NEOPLASMS; MELANOMA; MICE; MICE, SCID; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; SULFONAMIDES; TIME FACTORS; TRANSFECTION; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952818892     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791190184     Document Type: Article

References (44)

1. Tamura, K.; Fukuoka, M. Molecular target-based cancer therapy: tyrosine kinase inhibitors. Int. J. Clin. Oncol. 2003, 8, 207-211.
2. Press, M. F.; Lenz, H. J. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007, 67, 2045-2075.
3. Bottaro, D. P.; Rubin, J. S.; Faletto, D. L.; Chan, A. M.; Kmiecik, T. E.; Vande Woude G. F.; Aaronson, S. A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251, 802-804.
4. Comoglio, P. M.; Trusolino L. Invasive growth: from development to metastasis. J. Clin. Invest. 2002, 109, 857-862.
5. Trusolino, L.; Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2002, 2, 289-300.
6. Faletto, D. L.; Tsarfaty, I.; Kmiecik, T. E.; Gonzatti, M.; Suzuki, T.; Vande Woude, G. F. Evidence for non-covalent clusters of the c-met proto-oncogene product. Oncogene 1992, 7, 1149-1157.
7. Ma, P. C.; Maulik, G.; Christensen, J.; Salgia, R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003, 22, 309-325.
8. Corso, S.; Comoglio, P. M.; Giordano, S. Cancer therapy: can the challenge be MET? Trends Mol. Med. 2005, 11, 284-292.
9. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G. F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4, 915-925.
10. Di Renzo, M. F.; Olivero, M.; Giacomini, A.; Porte, H.; Chastre, E.; Mirossay, L.; Nordlinger, B.; Bretti, S.; Bottardi, S.; Giordano, S.; et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1995, 1, 147-154.
11. Onozato, R.; Kosaka, T.; Kuwano, H.; Sekido, Y.; Yatabe, Y.; Mitsudomi, T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J. Thorac. Oncol. 2009, 4, 5-11.
12. Migliore, C.; Giordano, S. Molecular cancer therapy: can our expectation be MET? Eur. J. Cancer 2008, 44, 641-651.
13. Linehan, W. M.; Pinto, P. A.; Srinivasan, R.; Merino, M.; Choyke, P.; Choyke, L.; Coleman, J.; Toro, J.; Glenn, G.; Vocke, C.; Zbar, B.; Schmidt, L. S.; Bottaro, D.; Neckers, L. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res. 2007, 13, 671s-679s.
14. Ma, P. C.; Kijima, T.; Maulik, G.; Fox, E. A.; Sattler, M.; Griffin, J. D.; Johnson, B. E.; Salgia, R. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003, 63, 6272-6281.
15. Yu, J.; Miehlke, S.; Ebert, M. P.; Hoffmann, J.; Breidert, M.; Alpen, B.; Starzynska, T.; Stolte, Prof. M.; Malfertheiner, P.; Bayerdorffer, E. Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer 2000, 88, 1801-1806.
16. Morotti, A.; Mila, S.; Accornero, P.; Tagliabue, E.; Ponzetto, C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002, 21, 4885-4893.
17. Garbe, C.; Leiter, U. Melanoma epidemiology and trends. Clin. Dermatol. 2009, 27, 3-9.
18. Hsu, M. Y.; Meier, F.; Herlyn, M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002, 70, 522-536.
19. Natali, P. G.; Nicotra, M. R.; Di Renzo, M. F.; Prat, M.; Bigotti, A.; Cavaliere, R.; Comoglio, P. M. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br. J. Cancer 1993, 68, 746-750.
20. Li, G.; Schaider, H.; Satyamoorthy, K.; Hanakawa, Y.; Hashimoto, K.; Herlyn, M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001, 20, 8125-8135.
21. McGill, G. G.; Haq, R.; Nishimura, E. K.; Fisher, D. E. c-Met expression is regulated by Mitf in the melanocyte lineage. J. Biol. Chem. 2006, 281, 10365-10373.
22. Riker, A. I.; Enkemann, S. A.; Fodstad, O.; Liu, S.; Ren, S.; Morris, C.; Xi, Y.; Howell P.; Metge, B.; Samant, R. S.; Shevde, L. A.; Li, W.; Eschrich, S.; Daud, A.; Ju, J.; Matta, J. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med. Genomics 2008, 1, 13.
23. Nambiar, S.; Mirmohammadsadegh, A.; Doroudi, R.; Gustrau, A.; Marini, A.; Roeder, G.; Ruzicka, T.; Hengge, U. R. Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Arch. Dermatol. 2005, 141, 165-173.
24. Cruz, J.; Reis-Filho, J. S.; Silva, P.; Lopes, J. M. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003, 65, 72-82.
25. Puri, N.; Ahmed, S.; Janamanchi, V.; Tretiakova, M.; Zumba, O.; Krausz, T.; Jagadeeswaran, R.; Salgia, R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin. Cancer Res. 2007, 13, 2246-2253.
26. Seidl, H.; Weger, W.; Wolf, P.; Kerl, H.; Schaider, H. Lack of oncogenic mutations in the c-Met catalytic tyrosine kinase domain in acral lentiginous melanoma. Int. J. Dermatol. 2008, 47, 1327-1329.
27. Ladanyi, A.; Timar, J.; Paku, S.; Molnar, G.; Lapis, K. Selection and characterization of human melanoma lines with different livercolonizing capacity. Int. J. Cancer 1990, 46, 456-461.
28. Sattler, M.; Pride, Y. B.; Ma, P.; Gramlich, J. L.; Chu, S. C.; Quinnan, L. A.; Shirazian, S.; Liang, C.; Podar, K.; Christensen, J. G.; Salgia, R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003, 63, 5462-5469.
29. Vermes, I.; Haanen, C.; Steffens-Nakken, H.; Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 1995, 184, 39-51.
30. Albini, A.; Iwamoto, Y.; Kleinman, H. K.; Martin, G. R.; Aaronson, S. A.; Kozlowski, J. M.; McEwan, R. N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47, 3239-3245.
31. Jiang, W.; Hiscox, S.; Matsumoto, K.; Nakamura, T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol. Hematol. 1999, 29, 209-48.
32. Haddad, R.; Lipson, K. E.; Webb, C. P. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res. 2001, 21, 4243-4252.
33. Longati, P.; Comoglio, P. M.; Bardelli, A. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Curr. Drug Targets 2001, 2, 41-55.
34. Lengyel, E.; Sawada, K.; Salgia, R. Tyrosine kinase mutations in human cancer. Curr. Mol. Med. 2007, 7, 77-84.
35. Rusciano, D.; Lorenzoni, P.; Burger, M. M. Expression of constitutively activated hepatocyte growth factor/scatter factor receptor (c-met) in B16 melanoma cells selected for enhanced liver colonization. Oncogene 1995, 11, 1979-1987.
36. Rusciano, D.; Lorenzoni, P.; Burger, M. M. Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity. J. Biol. Chem. 1996, 271, 20763-20769.
37. Fazekas, K.; Csuka, O.; Koves, I.; Raso, E.; Timar, J. Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis. Clin. Exp. Metastasis 2000, 18, 639-649.
38. Danilkovitch-Miagkova, A.; Zbar, B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 2002, 109, 863-867.
39. Graziani, A.; Gramaglia, D.; Cantley, L. C.; Comoglio, P. M. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J. Biol. Chem. 1991, 266, 22087-22090.
40. Xiao, G. H.; Jeffers, M.; Bellacosa, A.; Mitsuuchi, Y.; Vande Woude, G. F.; Testa, J. R. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. USA 2001, 98, 247-252.
41. Toker, A. Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol. Pharmacol. 2000, 57, 652-658.
42. Trusolino, L.; Cavassa, S.; Angelini, P.; Ando, M.; Bertotti, A.; Comoglio, P. M.; Boccaccio, C. HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J. 2000, 14, 1629-1640.
43. Wells, C. M.; Abo, A.; Ridley, A. J. PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J. Cell Sci. 2002, 115, 3947-3956.
44. Migliore, C.; Petrelli, A.; Ghiso, E.; Corso, S.; Capparuccia, L.; Eramo, A.; Comoglio, P. M.; Giordano, S. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 2008, 68, 10128-10136.